Back to top
more

Elanco Animal Health (ELAN)

(Delayed Data from NYSE)

$14.07 USD

14.07
6,323,568

-0.43 (-2.97%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $14.05 -0.02 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why Elanco Animal Health Incorporated (ELAN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Elanco (ELAN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Elanco (ELAN) stock based on the movements in the options market lately.

Elanco Animal Health Incorporated (ELAN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 46.15% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline

by Zacks Equity Research

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.21% and 3.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 25% and 0.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Elanco (ELAN)

by Zacks Equity Research

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed (CHE) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 2.82% and 1.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings Estimates

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 38.46% and 0.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AlerisLife (ALR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Five Star (ALR) delivered earnings and revenue surprises of -33.33% and 4.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Aveanna Healthcare (AVAH) Q2 Earnings Expected to Decline

by Zacks Equity Research

Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DaVita HealthCare (DVA) Tops Q2 Earnings Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 9% and 0.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) Q2 Earnings Beat Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Elanco (ELAN) This Earnings Season?

by Zacks Equity Research

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

U.S. Physical Therapy (USPH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 3.17% and 1.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Debasmita Chatterjee headshot

3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1

by Debasmita Chatterjee

Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.

Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.